« Previous
Next »
Titles
- Recognition and withdrawal of voluntary consensus standards: guidance for industry and Food and Drug Administration staff1
- Recommendations for clinical laboratory improvement amendments of 1988 (CLIA) waiver applications for manufacturers of in vitro diagnostic devices: guidance for industry and Food and Drug Administration staff1
- Recommendations for dual 510(k) and CLIA waiver by application studies: guidance for industry and Food and Drug Administration staff1
- Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components1
- Regulatory considerations for human cells, tissues, and cellular and tissue-based products: minimal manipulation and homologous use : guidance for industry and Food and Drug Administration staff1
- Required warnings for cigarette packages and advertisements: small entity compliance guide (revised)1
- Resuming normal drug and biologics manufacturing operations during the COVID-19 public health emergency1
- Revised recommendations for reducing the risk of human immunodeficiency virus transmission by blood and blood products1
- Revised recommendations to reduce the risk of transfusion-transmitted malaria1
- Risk evaluation and mitigation strategies: modifications and revisions1